Enhertu Injection, Powder, Lyophilized, For Solution
Product Images NDC 65597-406

12 FDA label images from Daiichi Sankyo Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Enhertu (NDC 65597-406). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Daiichi Sankyo Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Enhertu 01)

Chemical Structure (Enhertu 01)
Chemical structure of fam-trastuzumab deruxtecan-nxki, showing its monoclonal antibody (mAb) linked via a linker to approximately eight deruxtecan molecules, the topoisomerase I inhibitor component.*
FDA Label Image

Figure 1 (Enhertu 02)

Figure 1 (Enhertu 02)
A Kaplan-Meier progression-free survival curve comparing Enhertu (fam-trastuzumab deruxtecan-nxki) versus ado-trastuzumab emtansine over 32 months. The y-axis shows progression-free survival percentage, and the x-axis shows time in months. The graph includes number at risk tables for both treatments.*
FDA Label Image

Figure 2 (Enhertu 03)

Figure 2 (Enhertu 03)
A Kaplan-Meier overall survival curve comparing Enhertu (fam-trastuzumab deruxtecan-nxki) versus Irinotecan or Paclitaxel over a 24-month period. The vertical axis represents overall survival percentage, and the horizontal axis shows time in months. The chart includes numbers at risk for both treatment groups at various time points.*
FDA Label Image

Figure 3 (Enhertu 04)

Figure 3 (Enhertu 04)
Packaging label for Enhertu injection, powder, lyophilized, for solution, 100 mg per vial. The label specifies the drug fam-trastuzumab deruxtecan-nxki, intended for intravenous infusion. It includes storage instructions to keep refrigerated, single-dose vial information, and mentions it is a hazardous drug. The labeler is Daiichi Sankyo Inc., co-marketed with AstraZeneca, with a Product NDC of 65597-406. Additional details include contents and reconstitution instructions.*
FDA Label Image

Figure 4 (Enhertu 05)

Figure 4 (Enhertu 05)
A Kaplan-Meier survival curve chart showing overall survival percentage over time in months. It compares two groups: Enhertu (n=261) and Ado-trastuzumab emtansine (n=263). The vertical axis represents overall survival percentage from 0% to 100%, and the horizontal axis shows time in months up to 47. The chart includes the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 5 (Enhertu 06)

Figure 5 (Enhertu 06)
A Kaplan-Meier survival plot depicting progression-free survival (%) over time in months for two groups: Enhertu (fam-trastuzumab deruxtecan-nxki) with 406 participants and Treatment of Physician's Choice with 202 participants. The Enhertu group shows higher survival rates throughout the 46-month period. Below the graph, the number at risk is displayed by time points for both groups.*
FDA Label Image

Figure 6 (Enhertu 07)

Figure 6 (Enhertu 07)
A Kaplan-Meier survival curve comparing overall survival percentages over time in months between two groups: patients treated with Enhertu (n=406) and those receiving treatment of physician's choice (n=202). The graph includes number at risk tables for both groups over the study duration up to 46 months.*
FDA Label Image

Figure 7 (Enhertu 08)

Figure 7 (Enhertu 08)
A Kaplan-Meier curve illustrating the probability of progression-free survival (%) over time in months for two groups: patients treated with Enhertu (n=436) and patients treated with chemotherapy (n=430). The graph shows higher progression-free survival probabilities for Enhertu throughout the observation period of up to 39 months. Below the graph, a table displays the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 8 (Enhertu 09)

Figure 8 (Enhertu 09)
A Kaplan-Meier survival curve comparing overall survival percentage over time in months between two groups: patients treated with Enhertu and patients receiving chemotherapy. The chart includes censored data points and a table below indicating the number of patients at risk at various time intervals up to 34 months.*
FDA Label Image

Figure 9 (Enhertu 10)

Figure 9 (Enhertu 10)
A Kaplan-Meier survival curve chart comparing progression-free survival percentage over time (months) between Enhertu and chemotherapy groups. The chart shows two lines: one for Enhertu (black) and one for chemotherapy (gray), with data points marked for censored observations. A table below lists the number of patients at risk for both groups at various time points up to 29 months.*
FDA Label Image

Figure 10 (Enhertu 11)

Figure 10 (Enhertu 11)
A Kaplan-Meier survival curve chart comparing overall survival percentage over time in months for Enhertu versus Irinotecan or Paclitaxel. The chart shows two survival curves with the number at risk below the x-axis for both treatment groups from 0 to 24 months.*
FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Principal Display Panel (100 mg Vial Carton)
Enhertu (fam-trastuzumab deruxtecan-nxki) injection powder, lyophilized for solution, 100 mg per vial. The label indicates it is for intravenous infusion only, single-dose vial, and a hazardous drug. It is manufactured and marketed by Daiichi Sankyo Inc. and AstraZeneca. Storage requires refrigeration at 2°C to 8°C and protection from light. The packaging includes detailed dosing, storage, and preparation instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.